Tim Seymour, managing partner of Triogem Asset Management, said investors have been "poorly positioned" with the expectation that yields were going to increase in 2014 so far. However, he argued that the U.S. economy is doing pretty good and that yields will eventually head higher because of this, not lower.
Time (TIME) is reportedly in advanced talks to acquire a stake in Vice Media, which would value Vice at roughly $2.2 billion. Dan Nathan, co-founder and editor of riskreversal.com, said the valuation of Vice is likely to continue moving higher after this deal because it has successfully built a "great business model."
Sony (SNE) announced its Playstation TV on Wednesday. Seymour said that it's exciting news, although the technology has been around for a while and it will pit Sony against Microsoft (MSFT). He added that Sony may struggle after the next six to nine months but seems to have a bottom near $16.
Las Vegas Sands (LVS) was downgraded by UBS to hold from buy. Kelly said the slowing revenue from Macau will likely weigh on the company's results. It's "going to be challenged for a while," he added.Nathan pointed out that 75% of Wynn Resorts' (WYNN) profits come from Macau, and a slowdown in the region will certainly hurt the company. He "wouldn't touch it." CNBC's Meg Tirrell was a guest on the show to discuss some up-and-coming products and companies in the health care technology space. Covidien (COV) bought Given Imaging for $860 million 2013. The company now has a device that allows patients to ingest a "camera pill" that takes photos of the digestive tract. It could perhaps eliminate the colonoscopy. Other companies, such as Sanofi (SNY) and Illumina (ILMN) are creating mobile applications that can benefit both patients and doctors. GlaxoSmithKline (GSK) is also working on what it called Electroceuticals, which is where rice-sized electrical devices attach to patients' nerves. The treatment may help treat diabetes, obesity and hypertension but is likely 10 years away from becoming reality. Adami said Covidien is not an earnings or valuation play, it's an investment in the future. It still make sense to own despite the recent run-up in the share price, he urged. Nathan liked shares of GlaxoSmithKline, which are 5% from the all-time highs. Technically, the stock looks great, he said, along with a solid dividend yield of 4.8%.